BACKGROUND: Heart failure (HF) readmission results in substantial expenditure on HF management. This study aimed to evaluate the readmission rate, outcome, and predictors of HF readmission. METHODS: Patients with reduced left ventricular ejection fraction (LVEF < 40%) who were admitted for acute decompensation of de novo HF were enrolled to analyze readmission rate, mortality and predictors of readmission. RESULTS: A total of 433 de novo HF patients with LVEF < 40% were enrolled during the period August 2013 to December 2014. The in-hospital and 6-month mortality rates were 3.9% and 15.2%, respectively. In those patients surviving the index HF hospitalization, the 30-day and 6-month readmission rates were 10.9% and 27%, respectively. At the end of the 6-month follow-up, the readmission group had higher mortality than the non-readmission group (27.66% vs. 10.36%; p = 0.001). The survivors of the 30-day readmission had similar mortality rates at 6 months, regardless of the cause of readmission (cardiovascular vs. non-cardiovascular: 25% vs. 30.43%, p = 0.677). Among all the parameters, prescription of beta blockers independently reduced the risk of 30-day readmission (odds ratio 0.15; 95% confidence interval 0.02-0.99; p = 0.049). CONCLUSIONS: Those HF patients who suffered from 30-day readmission had worse prognosis at the 6-month follow-up. Regardless of the readmission causes, the patients surviving the 30-day readmission had similar mortality rates at 6-month follow-up. These results underscored the importance of reducing readmission as a means to improve HF outcome.
BACKGROUND:Heart failure (HF) readmission results in substantial expenditure on HF management. This study aimed to evaluate the readmission rate, outcome, and predictors of HF readmission. METHODS:Patients with reduced left ventricular ejection fraction (LVEF < 40%) who were admitted for acute decompensation of de novo HF were enrolled to analyze readmission rate, mortality and predictors of readmission. RESULTS: A total of 433 de novo HF patients with LVEF < 40% were enrolled during the period August 2013 to December 2014. The in-hospital and 6-month mortality rates were 3.9% and 15.2%, respectively. In those patients surviving the index HF hospitalization, the 30-day and 6-month readmission rates were 10.9% and 27%, respectively. At the end of the 6-month follow-up, the readmission group had higher mortality than the non-readmission group (27.66% vs. 10.36%; p = 0.001). The survivors of the 30-day readmission had similar mortality rates at 6 months, regardless of the cause of readmission (cardiovascular vs. non-cardiovascular: 25% vs. 30.43%, p = 0.677). Among all the parameters, prescription of beta blockers independently reduced the risk of 30-day readmission (odds ratio 0.15; 95% confidence interval 0.02-0.99; p = 0.049). CONCLUSIONS: Those HF patients who suffered from 30-day readmission had worse prognosis at the 6-month follow-up. Regardless of the readmission causes, the patients surviving the 30-day readmission had similar mortality rates at 6-month follow-up. These results underscored the importance of reducing readmission as a means to improve HF outcome.
Authors: G Michael Felker; Jeffrey D Leimberger; Robert M Califf; Michael S Cuffe; Barry M Massie; Kirkwood F Adams; Mihai Gheorghiade; Christopher M O'Connor Journal: J Card Fail Date: 2004-12 Impact factor: 5.712
Authors: Robb D Kociol; John R Horton; Gregg C Fonarow; Eric M Reyes; Linda K Shaw; Christopher M O'Connor; G Michael Felker; Adrian F Hernandez Journal: Circ Heart Fail Date: 2011-07-08 Impact factor: 8.790
Authors: Antonio Zapatero; Raquel Barba; Noemi Gonzalez; Juan E Losa; Susana Plaza; Jesús Canora; Javier Marco Journal: Rev Esp Cardiol (Engl Ed) Date: 2011-11-30
Authors: Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Ferenc Follath; Veli-Pekka Harjola; Matthias Hochadel; Michel Komajda; Johan Lassus; Jose Luis Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi Journal: Eur Heart J Date: 2006-09-25 Impact factor: 29.983
Authors: Joseph S Ross; Jersey Chen; Zhenqiu Lin; Héctor Bueno; Jeptha P Curtis; Patricia S Keenan; Sharon-Lise T Normand; Geoffrey Schreiner; John A Spertus; Maria T Vidán; Yongfei Wang; Yun Wang; Harlan M Krumholz Journal: Circ Heart Fail Date: 2009-11-10 Impact factor: 8.790
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Madeline R Sterling; Monika M Safford; Kathryn Goggins; Sam K Nwosu; Jonathan S Schildcrout; Kenneth A Wallston; Amanda S Mixon; Russell L Rothman; Sunil Kripalani Journal: J Hosp Med Date: 2018-02-12 Impact factor: 2.960